Astel­las' menopause drug hit by FDA de­lay af­ter spend­ing $97M on a pri­or­i­ty re­view vouch­er

In Au­gust, Astel­las an­nounced that an ap­pli­ca­tion for its menopausal symp­tom drug fe­zo­line­tant had been ac­cept­ed, and it used a pri­or­i­ty re­view vouch­er — to which …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.